Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376409 · ClinicalTrials.gov registry record · NA
Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females
A NA study, sponsored by Nutraceutical Wellness.
- Completed
- Registry status
- NA
- Development phase
- 181
- Enrollment target
NCT06376409: Completed NA study, sponsored by Nutraceutical Wellness.
NCT06376409 is a NA study that has completed, run by Nutraceutical Wellness. The registered enrollment target is 181 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376409, a NA study, has completed, sponsored by Nutraceutical Wellness.
- COMPLETED
- Registry status
- NA
- Development phase
- 181 participants
- Enrollment target
Study Summary
A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.
Primary Outcome
The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.
Interventions
- DIETARY_SUPPLEMENT Nutrafol Women's Balance Hair Growth Supplement
- DIETARY_SUPPLEMENT Nutrafol Women's Vegan Hair Growth Supplement
- DIETARY_SUPPLEMENT Nutrafol Women's Postpartum Hair Growth Supplement
- DIETARY_SUPPLEMENT Nutrafol Women's Hair Growth Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2024-05-06 |
| Est. Completion | 2025-06-18 |
| Phase | NA |
What the finished NCT06376409 record still lists
NCT06376409 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 4 interventions - of which Nutrafol Women's Balance Hair Growth Supplement is the first listed.
NCT06376409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06376409 about?
NCT06376409 is a clinical study titled "Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females". A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.
What is the current status of trial NCT06376409?
This trial is currently completed. It is a NA study. The enrollment target is 181 participants. The study started on 2024-05-06. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT06376409?
The interventions under investigation include: Nutrafol Women's Balance Hair Growth Supplement (DIETARY_SUPPLEMENT), Nutrafol Women's Vegan Hair Growth Supplement (DIETARY_SUPPLEMENT), Nutrafol Women's Postpartum Hair Growth Supplement (DIETARY_SUPPLEMENT), Nutrafol Women's Hair Growth Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06376409?
This trial is sponsored by Nutraceutical Wellness, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06376409's enrollment target sits among peer trials
181 586th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI